Should prophylaxis for Pneumocystis jirovecii pneumonia be considered in patients with a CD4+ count higher than 200 cells/μl?

Orna Nitzan Avi Peretz Nina Pastukh Margalit Lorber

AIDS

aInfectious Disease Unit, Baruch-Padeh Medical Center, Poriya bFaculty of Medicine, Bar Ilan University, Galilee cClinical Microbiology Laboratory, Baruch-Padeh Medical Center, Poriya dThe Institute of Clinical Immunology, Allergy and AIDS, Rambam Medical Center eRappaport Faculty of Medicine, Technion, Haifa, Israel.

Published: November 2015

Download full-text PDF	Source
http://dx.doi.org/10.1097/QAD.0000000000000881	DOI Listing

Publication Analysis

Top Keywords

prophylaxis pneumocystis

pneumocystis jirovecii

jirovecii pneumonia

pneumonia considered

considered patients

patients cd4+

cd4+ count

count higher

higher 200

200 cells/μl?

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!